0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Hematology

Ernest Beutler, MD
JAMA. 1987;258(16):2250-2252. doi:10.1001/jama.1987.03400160104024.
Text Size: A A A
Published online

The impact of molecular biology on the practice of medicine has been particularly evident in hematology. The technology that has made it possible to determine the fine structure of genes has not only increased our understanding of basic regulatory processes, but has also made possible therapeutic and diagnostic feats that previously were out of reach.

Using the techniques of molecular biology, sufficient quantities of biologically active proteins have been synthesized to treat patients with certain hematologic disorders. One product, interferon alfa, found to be effective in the treatment of hairy-cell leukemia1,2 and chronic granulocytic leukemia,3 is already commercially available in the United States. Others, including tissue plasminogen activator, erythropoietin (EPO),4,5 and interleukin 2, have already undergone extensive clinical trials and may soon be generally available. In the case of other mediators, such as tumor necrosis factor/cachectin, granulocyte-monocyte colony stimulating factor, granulocyte stimulating factor, macrophage stimulating factor, and

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();